Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$191.17 USD

191.17
9,472,615

+0.32 (0.17%)

Updated Oct 15, 2025 04:00 PM ET

After-Market: $190.75 -0.42 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 243)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Are You Looking for a High-Growth Dividend Stock? Johnson & Johnson (JNJ) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

    Sweta Killa headshot

    Healthcare ETF (IYH) Hits New 52-Week High

    by Sweta Killa

    This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?

      Zacks Equity Research

      Johnson & Johnson (JNJ) Stock Moves -0.04%: What You Should Know

      by Zacks Equity Research

      Johnson & Johnson (JNJ) closed the most recent trading day at $138.17, moving -0.04% from the previous trading session.

        Zacks Equity Research

        Women Health a Prime Concern Worldwide: 3 Stocks in Focus

        by Zacks Equity Research

        Women health care gradually gaining importance globally, investors might keep an eye on a few stocks.

          Zacks Equity Research

          Geron's Stock Plunges as J&J Ends Imetelstat Collaboration

          by Zacks Equity Research

          Geron (GERN) announces termination of collaboration with J&J for development of its sole pipeline candidate, imetelstat.

            Zacks Equity Research

            Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA

            by Zacks Equity Research

            FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.

              Zacks Equity Research

              Glaxo's Tuberculosis Vaccine Positive in Mid-Stage Study

              by Zacks Equity Research

              Glaxo's (GSK) vaccine candidate, M72/AS01E, achieves significant reduction in incidence of pulmonary tuberculosis in HIV-negative patients with latent tuberculosis infection.

                Zacks Equity Research

                The Zacks Analyst Blog Highlights: Johnson & Johnson, Visa, Verizon, Alphabet and Altria

                by Zacks Equity Research

                The Zacks Analyst Blog Highlights: Johnson & Johnson, Visa, Verizon, Alphabet and Altria

                  Kevin Cook headshot

                  Bull of the Day: Penumbra (PEN)

                  by Kevin Cook

                  Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech

                    Mark Vickery headshot

                    Top Research Reports for Johnson & Johnson, Visa & Verizon

                    by Mark Vickery

                    Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Visa (V) and Verizon (VZ).

                      Zacks Equity Research

                      J&J's Esketamine Fails to Meet Endpoint in Phase III Study

                      by Zacks Equity Research

                      J&J's (JNJ) late-stage candidate, esketamine nasal spray, fails to show statistical significance for the primary endpoint in a phase III study on patients with treatment-resistant depression.

                        Zacks Equity Research

                        AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk

                        by Zacks Equity Research

                        AstraZeneca's (AZN) Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study.

                          Zacks Equity Research

                          J&J Files NDA for Erdafitinib in Urothelial Cancer Indication

                          by Zacks Equity Research

                          Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.

                            Zacks Equity Research

                            Aduro's Cancer Arm & Strong Collaborations Boost Growth

                            by Zacks Equity Research

                            Aduro focuses on a broad pipeline of novel immunotherapies, developed for treating various types of cancers. Its collaboration agreements with large pharma companies fetch in regular funds.

                              Zacks Equity Research

                              Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV

                              by Zacks Equity Research

                              Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.

                                Zacks Equity Research

                                Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

                                by Zacks Equity Research

                                Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.

                                  Zacks Equity Research

                                  Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again

                                  by Zacks Equity Research

                                  Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

                                    Kinjel Shah headshot

                                    Is Artificial Intelligence the Next Big Thing in Biotech?

                                    by Kinjel Shah

                                    Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.

                                      Zacks Equity Research

                                      Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

                                      by Zacks Equity Research

                                      Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

                                        Zacks Equity Research

                                        Pharma/Biotech Stocks to Watch This Prostate Cancer Month

                                        by Zacks Equity Research

                                        Here we highlight a few companies that are focused on developing treatments for prostate cancer.

                                          Zacks Equity Research

                                          Shire's ADHD Portfolio Remains Strong Amid Competition

                                          by Zacks Equity Research

                                          Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.

                                            Zacks Equity Research

                                            Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod

                                            by Zacks Equity Research

                                            Perrigo (PRGO) announces approval of over-the-counter equivalent of Imodium Multi-Symptom Relief tablet in the United States.

                                              Zacks Equity Research

                                              The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

                                              by Zacks Equity Research

                                              The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

                                                Zacks Equity Research

                                                Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus

                                                by Zacks Equity Research

                                                Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.

                                                  Kinjel Shah headshot

                                                  Lilly, Teva, Pfizer & Others Await FDA Decisions in September

                                                  by Kinjel Shah

                                                  FDA grants approval to 34 new treatments this year so far.